Notes

Factor associated with Alzheimer's disease biomarkers along with risks to mental disability and decline throughout the Alzheimer's disease continuum.
Affinity maturation and structure-guided design of multivalency yielded a trivalent nanobody, mNb6-tri, with femtomolar affinity for SARS-CoV-2 Spike and picomolar neutralization of SARS-CoV-2 infection. mNb6-tri retains stability and function after aerosolization, lyophilization, and heat treatment. selleck chemical These properties may enable aerosol-mediated delivery of this potent neutralizer directly to the airway epithelia, promising to yield a widely deployable, patient-friendly prophylactic and/or early infection therapeutic agent to stem the worst pandemic in a century.Antiviral therapeutics against SARS-CoV-2 are needed to treat the pandemic disease COVID-19. Pharmacological targeting of a host factor required for viral replication can suppress viral spread with a low probability of viral mutation leading to resistance. Here, we used a genome-wide loss of function CRISPR/Cas9 screen in human lung epithelial cells to identify potential host therapeutic targets. Validation of our screening hits revealed that the kinase SRPK1, together with the closely related SRPK2, were jointly essential for SARS-CoV-2 replication; inhibition of SRPK1/2 with small molecules led to a dramatic decrease (more than 100,000-fold) in SARS-CoV-2 virus production in immortalized and primary human lung cells. Subsequent biochemical studies revealed that SPRK1/2 phosphorylate the viral nucleocapsid (N) protein at sites highly conserved across human coronaviruses and, due to this conservation, even a distantly related coronavirus was highly sensitive to an SPRK1/2 inhibitor. Together, these data suggest that SRPK1/2-targeted therapies may be an efficacious strategy to prevent or treat COVID-19 and other coronavirus-mediated diseases.We determined the antigen binding activity of convalescent plasma units from 47 individuals with a history of non-severe COVID-19 using three clinical diagnostic serology assays (Beckman, DiaSorin, and Roche) with different SARS-CoV-2 targets. We compared these results with functional neutralization activity using a fluorescent reporter strain of SARS-CoV-2 in a microwell assay. This revealed positive correlations of varying strength (Spearman r = 0.37-0.52) between binding and neutralization. Donors age 48-75 had the highest neutralization activity. Units in the highest tertile of binding activity for each assay were enriched (75-82%) for those with the highest levels of neutralization.An effective vaccine is essential to controlling the spread of SARS-CoV-2 virus. Here, we describe an influenza-virus-based vaccine for SARS-CoV-2. We incorporated a membrane-anchored form of the SARS-CoV-2 Spike receptor binding domain (RBD) in place of the neuraminidase (NA) coding sequence in an influenza virus also possessing a mutation that reduces the affinity of hemagglutinin for its sialic acid receptor. The resulting ΔNA(RBD)-Flu virus can be generated by reverse genetics and grown to high titers in cell culture. A single-dose intranasal inoculation of mice with ΔNA(RBD)-Flu elicits serum neutralizing antibody titers against SAR-CoV-2 comparable to those observed in humans following natural infection (~1250). Furthermore, ΔNA(RBD)-Flu itself causes no apparent disease in mice. It might be possible to produce a vaccine similar to ΔNA(RBD)-Flu at scale by leveraging existing platforms for production of influenza vaccines.We studied the activity of a range of weakly basic and moderately lipophilic drugs against SARS CoV2 in Vero E6 cells, using Vero E6 survival, qPCR of viral genome and plaque forming assays. No clear relationship between their weakly basic and hydrophobic nature upon their activity was observed. However, the approved drugs ambroxol and ciprofloxacin showed potent activity at concentrations that are clinically relevant and within their known safety profiles, and so may provide potentially useful agents for preclinical and clinical studies in COVID-19.
SARS-coronavirus 2 (SARS-CoV-2) is currently causing a worldwide pandemic. Potential drugs identified for the treatment of SARS-CoV-2 infection include chloroquine (CQ), its derivative hydroxychloroquine (HCQ), and the anesthetic propofol. Their mechanism of action in SARS-CoV-2 infection is poorly understood. Recently, anesthetics, both general and local, were shown to disrupt ordered lipid domains. These same lipid domains recruit the SARS-CoV-2 surface receptor angiotensin converting enzyme 2 (ACE2) to an endocytic entry point and their disruption by cholesterol depletion decreases ACE2 recruitment and viral entry.

Viral entry was determined using a SARS-CoV-2 pseudovirus (SARS2-PV) and a luciferase reporter gene expressed by the virus after treatment of the cells with 50 μM propofol, tetracaine, HCQ, and erythromycin. HCQ disruption of monosialotetrahexosylganglioside1 (GM1) lipid rafts, phosphatidylinositol 4,5-bisphosphate (PIP
) domains, and ACE2 receptor at nanoscale distances was monitored by ruption of the membrane appears to also disrupt the production of host defense peptide, hence an antimicrobial such as erythromycin could be an important combined treatment. Nonetheless erythromycin has anti-SARS-CoV-2 activity and may combine with HCQ to reduce infection.

What is the molecular basis for antiviral activity of hydroxychloroquine and propofol?
Hydroxychloroquine disrupt lipid rafts similar to local and general anesthetics.
Since lipids cluster ACE2 and facilitate viral entry, hydroxychloroquine and anesthetics appear to inhibit viral entry by disrupting the lipid clustering and ACE2 localization.
Question What is the molecular basis for antiviral activity of hydroxychloroquine and propofol? Findings Hydroxychloroquine disrupt lipid rafts similar to local and general anesthetics. Meaning Since lipids cluster ACE2 and facilitate viral entry, hydroxychloroquine and anesthetics appear to inhibit viral entry by disrupting the lipid clustering and ACE2 localization.Granular ferric hydroxide (GFH) is often used for fixed bed adsorbent (FBA) columns in groundwater purification units around the world to remove arsenate contaminations. Groundwater can contain also other toxic (e.g., antimonite and vanadate) and non-toxic oxo-anions (phosphate and silicic acid) that are known to affect FBA lifetimes. Therefore, understanding the breakthrough of toxic compounds intended for removal by FBA is essential to their design, and is important to predict accurately breakthrough curves (BTCs) for FBAs in waterworks to plan future operating costs. Rapid small-scale column tests (RSCCT) and pilot-scale FBA were used to simulate vanadate BTCs for complex groundwater chemistries. The BTCs were simulated successfully using a homogeneous surface diffusion model (HSDM) combining equilibrium chemical adsorption and kinetic mass transfer. Adsorption parameters for various groundwater compositions were predicted using the CD-MUSIC surface complexation model, which was set up for the first time for akaganéite-based granular ferric hydroxide with a competitive multi-solute system.
Homepage: https://www.selleckchem.com/products/navoximod.html